NCCN® Duvelisib (COPIKTRA®) Update to Clinical Practice Guidelines in Oncology for CTCL
“We are very pleased to see COPIKTRA (duvelisib) added as a treatment option in the NCCN Guidelines for patients with CTCL (MFSS). We appreciate NCCN’s recognition of evidence showing COPIKTRA, as an oral dual PI3K inhibitor, to be a clinically important option in the treatment of T cell lymphomas,” said Dr. Christiane Langer, Senior Vice President, Head of Clinical & Medical Affairs at Secura Bio. “COPIKTRA is approved by the U.S. Food and Drug Administration for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (r/r CLL/SLL). The NCCN Guidelines also recommend COPIKTRA for relapsed/refractory peripheral T-cell lymphoma (PTCL). Currently we are advancing a Phase 3 trial (TERZO) evaluating COPIKTRA in patients with relapsed/refractory nodal T-cell lymphoma with a T follicular helper (TFH) phenotype. We look forward to building the clinical evidence that further defines COPIKTRA’s role across T-cell lymphomas where successful treatment options have proven challenging.”
Share:
More News
“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies
AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most
“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT
“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a